Psych Capital PLC - AUDITED RESULTS TO 30 APRIL 2022
Announcement provided by
Psych Capital Plc · PSY31/10/2022 16:04
31 October 2022
PSYCH CAPITAL PLC
AQSE: PSY
("Psych" or "the Company")
AUDITED RESULTS FOR THE YEAR ENDED 30 APRIL 2022
Psych Capital plc, the AQSE traded psychedelic healthcare incubation company, is pleased to announce its audited results for the year ended 30 April 2022.
The information set out below has been extracted from the Company's annual report and accounts for the year ended 30 April 2022 and the full report will shortly be available on the Company's website at https://psych.capital
"CHAIRMAN'S STATEMENT
We are pleased to present the results for Psych Capital Plc for the year ended 30 April 2022. The Company was admitted to the AQSE Growth market on 9 June 2022 and is the first pure-play psychedelic company to list in
The nascent and growing medical psychedelic industry has attracted a significant base of investors seeking to establish and scale businesses in a landscape showing scientific and commercial promise. The Company seeks to uncover opportunities at the forefront of the rapidly evolving regulatory landscape, developments in healthcare delivery frameworks, and scientific and clinical research, to address the unmet needs of patients in the
The Company is pursuing two core strategies:
· Identify, fund and support the building of future companies conducting clinical research programs to develop psychedelic drug development and therapeutic treatments; and
· Scaling and growing its business-to-business ("B2B") media and content platform (PSYCH) for the psychedelic science and healthcare industry.
Overview
During 2021, the Company invested in Awakn Life Sciences Corp. ("Awakn"), acquiring approximately 2% per cent of Awakn's issued share capital at the time of the investment. Awakn is a clinical biotech company researching, developing and delivering evidence-based psychedelic medicine to treat addiction and other mental health conditions. The team at Awakn have delivered progress on a number of fronts in 2022, including the successful completion of Phase One of its Drug Discovery Program, and the approval of Phase III of its Ketamine assisted therapy for alcohol use disorder program, with the National Institute for Health and Care Research ("NIHR"), a
The Company also acquired the PSYCH platform from Prohibition Holdings Limited. The platform is a business-to-business media and content platform for the psychedelic science and healthcare industry, and provides a resource for networking, intelligence and insights, servicing the industry through publications, newsletters and engaging events. The PSYCH Platform is revenue generative, with
PSYCH has amassed a significant global B2B audience, with subscribers to the platform growing by 38% since acquisition, to 37,000 readers. This is particularly impressive given the Company's lack of marketing activity. The platform also produces "The Psychedelics as a Medicine Report" series, now in its 3rd Edition, which has become one of the leading resources for the global industry, with over 2,000 downloads per edition, and which is recording record revenue in sponsorship from premium psychedelic companies, including Beckley Psytech, Atai, Braxia, Filament Health and Diamond.
Post year-end
The inaugural PSYCH Symposium was held in The National Gallery on 11 May 2022 in
In June 2022, we listed on the Aquis Exchange, making Psych Capital Plc the first pure play psychedelic focused company to list on
We are committed to advancing the case for regulatory reform in the
While most of the attention in the industry is focused on R&D and drug development, Psych Capital has conducted a full analysis of potential healthcare delivery frameworks to identify early-stage opportunities related to the implementation of psychedelics as medicine. This included a full mapping of companies, initiatives and projects that could impact the development of the sector. Alongside market analysis, Psych Capital explored investment opportunities into several companies and while no investment has been finalised to date, we have identified potential investments that could make a positive impact to the group in the future.
The management team and board has been strengthened by the appointment of an independent non-executive director upon admission to the AQSE, and subsequently a CFO, both of whom are seasoned finance professionals, with public markets, and regulatory expertise.
Outlook and prospects
Whilst macroeconomic pressure stemming from the conflict in
Our latest PSYCH reports forecast that the European economies stand to save over
Psych Capital, with our network of experts, proprietary market intelligence, and access to deal flow, is in a strong position to invest in early-stage opportunities in the medical psychedelic industry. We have been exploring several potential M&A transactions which have come to us at preferential valuations compared to the prior six months, and we look forward to updating the market on developments.
Joseph Colliver
Non-Executive Chairman
The Directors of the Company accept responsibility for the contents of this announcement.
ENQUIRIES:
Company:
Psych Capital plc
William Potts |
info@psych.capital |
Stephen Murphy |
AQSE Corporate Adviser:
Peterhouse Capital Limited
Guy Miller Mark Anwyl |
020 7469 0930 |
Statement of Comprehensive Income
|
|
|
Year ended 30 April 2022 |
|
|
|
£ |
|
|
|
|
Revenue |
|
|
62,228 |
Cost of sales |
|
|
(22,257) |
Gross profit |
|
|
39,971 |
|
|
|
|
Administrative expenses |
|
|
(622,445) |
Operating loss |
|
|
(582,474) |
|
|
|
|
Fair value gains on fixed asset investments |
|
|
38,541 |
Loss on ordinary activities before taxation |
|
|
(543,933) |
|
|
|
|
Income tax |
|
|
- |
Total comprehensive loss for the financial year |
|
|
(543,933) |
|
|
|
|
Basic loss per share attributable to owners of the parent |
|
|
0.012 |
Statement of Financial Position
|
|
As at 30 April 2022 |
|
|
£ |
Non-current Assets |
|
|
Intangible assets |
|
387,500 |
Investments |
|
338,542 |
Total Non-current Assets |
|
726,042 |
|
|
|
Current Assets |
|
|
Cash and cash equivalents |
|
322,634 |
Other receivables |
|
150,568 |
Total Current Assets |
|
473,202 |
|
|
|
Current Liabilities |
|
|
Trade and other payables |
|
723,177 |
Total Liabilities |
|
723,177 |
|
|
|
Net Current Assets/(Liabilities) |
|
(249,975) |
|
|
|
Net Assets |
|
476,067 |
|
|
|
Equity |
|
|
Issued share capital |
|
183,333 |
Share premium |
|
836,667 |
Retained earnings |
|
(543,933) |
Total Equity |
|
476,067 |
Statement of Changes in Equity
|
|
Share capital |
Share premium |
Retained earnings |
Total equity |
|
|
£ |
£ |
£ |
£ |
Transactions with equity owners |
|
|
|
|
|
At incorporation - issue of share capital 2 ordinary shares at |
|
- |
- |
- |
- |
Ordinary Shares issued 39,998 shares at |
|
4 |
- |
- |
4 |
Ordinary Shares issued |
|
183,329 |
836,667 |
- |
1,019,996 |
Total comprehensive income |
|
|
|
|
|
Total comprehensive income for the year ended 30 April 2022 |
|
- |
- |
(543,933) |
(543,933) |
As at 30 April 2022 |
|
183,333 |
836,667 |
(543,933) |
476,067 |
Statement of Cash Flows
|
|
|
Year ended 30 April 2022 |
|
|
|
£ |
|
|
|
|
Cash flows from operating activities |
|
|
|
Loss before tax |
|
|
(543,933) |
Adjusted for: |
|
|
|
Fair value gain on investments |
|
|
(38,541) |
Amortisation of intangible assets |
|
|
62,500 |
|
|
|
|
(Increase) in trade and other receivables |
|
|
(150,568) |
Increase in trade and other payables |
|
|
273,177 |
Net cash used in operating activities |
|
|
(397,365) |
|
|
|
|
Cash flows from investing activities |
|
|
|
Purchase of investments |
|
|
(240,001) |
Net cash used in investing activities |
|
|
(240,001) |
|
|
|
|
Cash flows from financing activities |
|
|
|
Proceeds from the issue of shares |
|
|
960,000 |
Net cash generated from financing activities |
|
|
960,000 |
|
|
|
|
Net increase in cash and cash equivalents |
|
|
322,634 |
Cash and cash equivalents at beginning of year |
|
|
- |
Cash and cash equivalents at end of year |
|
|
322,634" |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.